OverviewChartNewsTraderScreen

HSBC Knock-Out LLY/  DE000HS25QN8  /

Frankfurt Zert./HSBC
9/13/2024  9:35:29 PM Chg.-0.120 Bid9:59:03 PM Ask9:59:03 PM Underlying Strike price Expiration date Option type
3.110EUR -3.72% 3.110
Bid Size: 500,000		 3.130
Ask Size: 500,000		 Eli Lilly and Co 579.3661 USD 12/31/2078 Call
TeleTrader 9/9 Eli Lilly appoints Lucas Montarce as CFO
Newsfile Corp 8/28 The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire 8/27 Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...
GlobeNewswire 8/26 Eliem Therapeutics Announces Additions to its Leadership Team
GlobeNewswire 8/21 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 8/21 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 8/14 Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire 8/14 Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire 8/8 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 8/8 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
TeleTrader 8/8 US opens higher with data, earnings in focus
GlobeNewswire 8/8 ProQR Announces Second Quarter 2024 Operating and Financial Results
TeleTrader 8/8 Eli Lilly's Q2 revenue jumps 36% to $11.3B
GlobeNewswire 8/8 Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly
GlobeNewswire 8/7 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire 8/6 Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire 8/6 SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...
GlobeNewswire 8/2 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire 8/1 Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire 8/1 COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives
GlobeNewswire 8/1 Compass Pathways announces second quarter 2024 financial results and business highlights
GlobeNewswire 7/31 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFC, HMNF, MORF on Behalf of Shareholders
GlobeNewswire 7/31 MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Hold...
GlobeNewswire 7/31 Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
GlobeNewswire 7/31 HUTCHMED Reports 2024 Interim Results and Provides Business Updates